EG24459A - Soluble CTLA4 mutant molecules and uses thereof - Google Patents

Soluble CTLA4 mutant molecules and uses thereof

Info

Publication number
EG24459A
EG24459A EG20010548A EG20010548A EG24459A EG 24459 A EG24459 A EG 24459A EG 20010548 A EG20010548 A EG 20010548A EG 20010548 A EG20010548 A EG 20010548A EG 24459 A EG24459 A EG 24459A
Authority
EG
Egypt
Prior art keywords
soluble ctla4
mutant molecules
amino acid
ctla4
molecules
Prior art date
Application number
EG20010548A
Other languages
English (en)
Inventor
Robert J Peach
Joseph R Naemura
Peter S Linsley
Juergen Bajorath
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG24459A publication Critical patent/EG24459A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EG20010548A 2000-05-26 2001-05-23 Soluble CTLA4 mutant molecules and uses thereof EG24459A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
EG24459A true EG24459A (en) 2009-07-16

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EG20010548A EG24459A (en) 2000-05-26 2001-05-23 Soluble CTLA4 mutant molecules and uses thereof

Country Status (41)

Country Link
EP (3) EP1248802B9 (show.php)
JP (1) JP4328525B2 (show.php)
KR (2) KR100889887B1 (show.php)
CN (2) CN1309735C (show.php)
AR (1) AR031699A1 (show.php)
AT (1) ATE271066T1 (show.php)
AU (2) AU2001263466C1 (show.php)
BE (1) BE2011C041I2 (show.php)
BR (1) BRPI0111191B8 (show.php)
CA (1) CA2409748C (show.php)
CY (2) CY2011019I1 (show.php)
CZ (1) CZ304451B6 (show.php)
DE (2) DE60104282T2 (show.php)
DK (1) DK1248802T3 (show.php)
EC (1) ECSP024365A (show.php)
EE (2) EE05557B1 (show.php)
EG (1) EG24459A (show.php)
ES (2) ES2225549T3 (show.php)
FR (1) FR11C0053I2 (show.php)
GE (1) GEP20053658B (show.php)
HK (1) HK1048126B (show.php)
HU (2) HU228137B1 (show.php)
IL (1) IL152315A (show.php)
LT (1) LT5133B (show.php)
LU (1) LU91902I2 (show.php)
LV (1) LV12994B (show.php)
MX (1) MXPA02011534A (show.php)
MY (1) MY136113A (show.php)
NO (2) NO330797B1 (show.php)
PE (1) PE20011338A1 (show.php)
PL (1) PL206267B1 (show.php)
PT (1) PT1248802E (show.php)
RU (1) RU2283847C2 (show.php)
SI (1) SI1248802T1 (show.php)
SK (1) SK288131B6 (show.php)
TR (1) TR200402703T4 (show.php)
TW (2) TWI319405B (show.php)
UA (1) UA87432C2 (show.php)
UY (1) UY26723A1 (show.php)
WO (1) WO2001092337A2 (show.php)
ZA (1) ZA200208944B (show.php)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
RU2287340C2 (ru) 2000-07-03 2006-11-20 Бристол-Маерс Сквибб Компани Способы лечения ревматических заболеваний с применением растворимого ctla4
HU229680B1 (hu) 2001-05-23 2014-04-28 Bristol Myers Squibb Co Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
CA2511520A1 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TWI328614B (en) * 2002-12-23 2010-08-11 Bristol Myers Squibb Co Product quality enhancement in mammalian cell culture processes for protein production
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
ES2439641T3 (es) 2005-12-20 2014-01-24 Bristol-Myers Squibb Company Composiciones y procedimientos de producción de una composición
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CN101675074B (zh) 2006-12-20 2016-02-24 Mmr全球公司 抗体及其制备和使用方法
AU2008319053B2 (en) * 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
CN107056951A (zh) * 2008-10-02 2017-08-18 阿帕特夫研究和发展有限公司 Cd86拮抗物多靶点结合蛋白
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2545073B1 (en) * 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
US20120214204A1 (en) 2011-02-23 2012-08-23 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
DK3207938T3 (da) * 2012-05-11 2020-03-16 Medimmune Ltd Ctla-4-varianter
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
HUE042277T2 (hu) 2014-06-04 2019-06-28 Amgen Inc Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl
AU2015355087C1 (en) 2014-12-01 2025-10-30 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
EP3702470A3 (en) 2015-09-09 2020-10-07 The Trustees of Columbia University in the City of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3374493A1 (en) 2015-11-09 2018-09-19 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CN116942793A (zh) 2016-09-19 2023-10-27 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
CN116555353A (zh) 2017-04-20 2023-08-08 E开创生物技术股份有限公司 产生基因修改的动物的方法
KR102813968B1 (ko) * 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
AU2020338947A1 (en) 2019-08-27 2022-03-31 Tonix Pharma Limited Modified TFF2 polypeptides
MY190623A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
US12123879B2 (en) 2020-06-18 2024-10-22 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed C-terminal lysine
US20230287322A1 (en) 2020-07-28 2023-09-14 Seagen Inc. Methods and systems for producing polypeptides
CN118647416A (zh) 2021-12-16 2024-09-13 百时美施贵宝公司 用于病毒灭活的洗涤剂
CN119095875A (zh) 2022-03-02 2024-12-06 瑞泽恩制药公司 高滴度抗体的制造工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000019988A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
RU2287340C2 (ru) * 2000-07-03 2006-11-20 Бристол-Маерс Сквибб Компани Способы лечения ревматических заболеваний с применением растворимого ctla4

Also Published As

Publication number Publication date
KR100895134B1 (ko) 2009-05-04
PL366231A1 (en) 2005-01-24
EE201100050A (et) 2011-10-17
CN1309735C (zh) 2007-04-11
CN1441810A (zh) 2003-09-10
CN101255192A (zh) 2008-09-03
HUS1300012I1 (hu) 2016-08-29
NO20025656D0 (no) 2002-11-25
ES2225549T3 (es) 2005-03-16
NO2011027I2 (show.php) 2011-12-15
BR0111191A (pt) 2004-07-06
EP1248802B9 (en) 2005-05-11
AU2001263466C1 (en) 2006-10-26
HK1048126A1 (en) 2003-03-21
EP1536234A3 (en) 2009-06-03
CZ304451B6 (cs) 2014-05-14
DE122011100063I1 (de) 2012-06-14
NO330797B1 (no) 2011-07-18
DE60104282T2 (de) 2005-10-13
BE2011C041I2 (show.php) 2020-08-20
CA2409748A1 (en) 2001-12-06
ATE271066T1 (de) 2004-07-15
PT1248802E (pt) 2004-11-30
LV12994B (en) 2003-08-20
BRPI0111191B8 (pt) 2021-05-25
SK15702002A3 (sk) 2004-01-08
WO2001092337A2 (en) 2001-12-06
TW200906857A (en) 2009-02-16
KR20030009502A (ko) 2003-01-29
JP4328525B2 (ja) 2009-09-09
GEP20053658B (en) 2005-11-10
DK1248802T3 (da) 2004-11-15
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
TR200402703T4 (tr) 2004-11-22
AR031699A1 (es) 2003-10-01
EE05557B1 (et) 2012-08-15
EE200200659A (et) 2004-06-15
IL152315A0 (en) 2003-05-29
FR11C0053I2 (fr) 2013-01-11
TWI319405B (en) 2010-01-11
CY1117625T1 (el) 2017-04-26
ECSP024365A (es) 2003-03-31
HK1048126B (en) 2005-03-04
EP1536234A2 (en) 2005-06-01
CZ20023892A3 (cs) 2003-09-17
BRPI0111191B1 (pt) 2019-12-31
MXPA02011534A (es) 2004-08-12
UA87432C2 (uk) 2009-07-27
EE05458B1 (et) 2011-08-15
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (en) 2002-05-10
IL152315A (en) 2010-04-15
CA2409748C (en) 2008-09-16
EP1536234B1 (en) 2016-03-16
FR11C0053I1 (show.php) 2012-01-13
KR100889887B1 (ko) 2009-03-24
PL206267B1 (pl) 2010-07-30
HUP0302201A3 (en) 2010-01-28
EP1248802B1 (en) 2004-07-14
DE60104282D1 (de) 2004-08-19
HUP0302201A2 (hu) 2003-10-28
UY26723A1 (es) 2001-12-28
MY136113A (en) 2008-08-29
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
RU2283847C2 (ru) 2006-09-20
TWI314933B (en) 2009-09-21
LT5133B (lt) 2004-05-25
HK1071931A1 (en) 2005-08-05
ES2571852T3 (es) 2016-05-27
HU228137B1 (en) 2012-12-28
CY2011019I1 (el) 2016-12-14
JP2004511213A (ja) 2004-04-15
ZA200208944B (en) 2004-02-13
AU6346601A (en) 2001-12-11
LT2002114A (en) 2003-12-29
SI1248802T1 (en) 2005-02-28
AU2001263466B2 (en) 2006-04-27
NO2011027I1 (no) 2012-01-09
EP3029062A1 (en) 2016-06-08
NO20025656L (no) 2002-11-25
PE20011338A1 (es) 2002-01-13

Similar Documents

Publication Publication Date Title
EG24459A (en) Soluble CTLA4 mutant molecules and uses thereof
MX343752B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
SG156547A1 (en) Human monoclonal antibodies to ctla-4
EP1559795A3 (en) Neisseria genomic sequences and methods of their use
MX2007012222A (es) Metodo para tratamiento de trastornos inmunes asociados con trasplante de injerto con moleculas mutantes ctla4 solubles.